View Older Stories View More Recent Stories
-
Pfizer (PFE) PT Lowered to $30 at Bernstein; 'We Need to See More'
-
Pfizer (PFE) Announces New Chief Medical Officer
-
Summit Therapeutics (SMMT) Announces Clinical Trial Collaboration with Pfizer (PFE) to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
Pfizer (PFE) Will End Global Development and Commercialization of Beqvez - Nikkei
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
Pfizer (PFE) stock: What could right the ship according to Wolfe
-
RFK, Jr. said confirmed
-
Pfizer (PFE) Reports TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
-
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
-
House Speaker Johnson Says He Believes The White House Is Considering Exemptions To Reciprocal Tariffs Including Autos And Pharmaceuticals - Reuters
-
Pfizer (PFE): U.S. FDA Approves Pfizer’s ADCETRIS Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Pfizer (PFE) PT Raised to $34 at Jefferies
-
Pfizer (PFE) and Astellas PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of la/mUC
-
Pfizer (PFE) PT Lowered to $32 at Goldman Sachs
-
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
-
Pfizer (PFE) call put ratio 2.2 calls to 1 put with focus on June 28 calls
-
Pfizer's (PFE) BRAFTOVI Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
-
Pfizer (PFE) call put ratio 1 call to 1 put into quarter results
-
Moderna stock rises following RFK Jr's comments
-
Pfizer (PFE) to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
-
Pfizer (PFE) Said To Avoid Challenge From Activist Starboard For Now - Bloomberg
-
Pfizer (PFE) Intends To Sell About 700M Haleon (HLN) Shares
-
Pfizer (PFE) CEO: "all in" on obesity drug development - JPM Healthcare Conference
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Pfizer's (PFE) Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
-
Pfizer (PFE) call put ratio 2.8 calls to 1 put as share price up 1.1%
-
TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'
-
2025 Biopharma sector outlook
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Sangamo Therapeutics (SGMO) to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
-
Pfizer (PFE) Announces FDA Approval of BRAFTOVI Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
-
Pfizer (PFE) PT Lowered to $32 at Truist Securities
-
Bernstein on Pfizer's (PFE) FY2025 Guide: 'Nothing Too Surprising, But First Guide on Part D IRA Impact'
-
Pfizer (PFE) Reaffirms FY24 Guidance, Issues FY25 Guidance
-
Goldman Sachs Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.8% Yield
-
Pfizer's (PFE) IBRANCE in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast C
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Pfizer (PFE) PT Lowered to $33 at Guggenheim
-
Pfizer (PFE) PT Lowered to $28 at Leerink Partners
-
Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
-
Trump hosted the chief executives of Pfizer (PFE), Eli Lilly & Co. (LLY) - Axios
-
This big pharma stock offers an 'interesting near-term setup' says Morgan Stanley
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
UK's CMA: Competition Appeal Tribunal Fines Pfizer (PFE) and Flynn GBP 69M for Excessive Pricing
-
Pfizer (PFE) Appoints Chris Boshoff as Chief Scientific Officer and President of R&D
-
Pfizer (PFE) Announces EU Approval of HYMPAVZI for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
